Kyverna Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Kyverna Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 19, 2025, Steve Liapis, Ph.D. notified the board of directors (the “Board”) of Kyverna Therapeutics, Inc. (the “Company”) of his decision to resign from his position as a member of the Board and all committees thereof, effective September 30, 2025. Dr. Liapis’ resignation is not due to any disagreement with the Company relating to any of the Company’s operations, policies or practices.

The Board thanks Dr. Liapis for his years of service and valuable contributions to the Company.

Effective upon Dr. Liapis’ resignation, the size of the Board will be reduced from eight to seven directors. The Board has appointed Christi Shaw, a current member of the Board, to the Audit Committee of the Board to fill the vacancy on the committee upon Dr. Liapis’ resignation.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.